Recro Pharma, Inc., a clinical-stage specialty pharmaceutical developing non-opioid therapeutics for pain treatment, has announced the pricing of its initial public offering of 3.75 million shares of common stock at $8.00 per share. The offering was expected to close on March 12.

Justin P. Klein, Katayun I. Jaffari, Peter Jaslow, Carly O. Abrahamson, and Sandra Maki Hashima, all of Ballard Spahr's Securities team, with the support of D. Brian Shortell, Douglas M. Fox, Scott Towers, Steven B. King, and Richard S. Perelman, represented Recro in the IPO.

Related Practices

Business and Finance
Intellectual Property 
Life Sciences and Technology
Securities